CREB1 and gastric neuroendocrine tumor, well differentiated, low or intermediate grade: In our EWSR1/CREB1 fusion-positive GNET case, immunotherapy combined with targeted therapy was chosen as the rational and promising therapeutic option at the time of relapse, following a three-year disease-free interval after initial surgical management, which warrants further investigation.